- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06133088
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
Explore the Efficacy and Safety of Dalpiciclib Combined With Fluvestrant and Compound Gossypol Acetate Tablets in Advanced HR-positive and HER2-negative Breast Cancer After CDK4/6 Treatment Failed.
Study Overview
Status
Intervention / Treatment
Detailed Description
Dalpiciclib: According to the standard dose, 150mg orally for three weeks and stop for one week.
Fluvestrant: At the standard dose, 500mg once every four weeks. A further 500mg dose two weeks after the first dose.
Compound gossypol acetate tablets: 20mg once a day.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- zhejiangCH
-
Contact:
- Ying Xi Shao, doctor
- Phone Number: 15824113524
- Email: 15824113524@163.com
-
Principal Investigator:
- Ying Xi Shao, doctor
-
Principal Investigator:
- Jia Xiao Wang, doctor
-
Principal Investigator:
- Hong Xiao Fang, doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1.Written informed consent. 2.Women aged 18 years or older. 3.Eastern Cooperative Oncology Group(ECOG) has a physical fitness score of 0 or 1. 4.Life expectancy is more than six months. 5.Diagnosed as HR-positive HER2-negative metastatic breast cancer. 6.There was at least one measurable lesion according to RECIST 1.1. 7.Failed in treating with CDK4/6 inhibitors combined with endocrine therapy at the metastatic stage. 8.Good organ function. 9.Fertile female patients must have a negative serum pregnancy test within seven days prior to study treatment and consent to effective contraceptive use for 180 days from screening to the last dose of study treatment. 10.Female patients must agree not to breastfeed during the study period or for 180 days after the last dose of study therapy.
Exclusion Criteria:
1.Patients enrolled in any interventional clinical trial at the same time and received the investigational therapy ≤ four weeks prior to initiation of the regimen or at least five half-lives of the investigational drug. 2.Patients who had received radiation therapy with bone marrow coverage >20% within two weeks before the start of treatment, except for minor palliative radiation therapy more than one week before the first day of the study. 3.Patients with a visceral crisis, and requiring chemotherapy. 4.Patients allergic to dalpiciclib or compound gossyrol acetate tablets. 5.A history of platelet transfusion for chemotherapy-induced thrombocytopenia or prior cancer treatment (lasting > 4 weeks and associated with recent treatment) is known to result in ≥ grade 3 hematological toxicity. 6.The patient had any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 7.Patients have a severe, uncontrolled medical condition, a non-malignant systemic disease, or an active, uncontrolled infection. 8.Patients diagnosed, detected, or treated for another type of cancer within ≤2 years prior to beginning regimen therapy.
Patients with brain metastases or pial metastases uncontrolled. 9.Patients have received an allogeneic bone marrow transplant or double umbilical cord blood transplant. 10.Patients cannot swallow oral medications. 11.Patients with gastrointestinal disorders that may interfere with the absorption of investigational drugs. 12.Patients have had systemic active autoimmune disease (i.e., disease modulators, corticosteroids, or immunosuppressants) within the past two years. 13.Patients with a history of human immunodeficiency virus, active-hepatitis -B or C. 14.Pregnant or nursing women. Fertile adults without effective contraceptive methods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.
|
Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose. Compound gossyrol acetate tablet: 20mg daily. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to 24 months
|
ORR is defined as the percentage of patients who achieved a best overall response of Complete Response (CR) or Partial Response (PR), per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions as assessed by the Investigator: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: up to 24 months
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
|
up to 24 months
|
Clinical Benefit Rate (CBR)
Time Frame: up to 24 months
|
Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST v1.1.
|
up to 24 months
|
Duration of Overall Response(DoR)
Time Frame: up to 24 months
|
Time from first recording to CR or PR to disease progression or all-cause death.
|
up to 24 months
|
Time to response (TTR)
Time Frame: up to 24 months
|
TTR defined as the time from the date of the first dose of study treatment to the first objective tumor response when CR or PR is observed.
|
up to 24 months
|
Overall survival (OS)
Time Frame: up to 24 months
|
Time to death from any cause from the date of first dose of study treatment
|
up to 24 months
|
adverse event(AE)
Time Frame: Throughout the experiment, assessed up to 24 months.
|
Evaluation performed using the National Cancer Institute (NCI)- Standard for Common Terminology for Adverse Events (CTCAE)v.5.0.
|
Throughout the experiment, assessed up to 24 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory endpoint
Time Frame: Throughout the experiment, assessed up to 24 months.
|
Correlation between the expression levels of LRPPRC and CDK6 and the efficacy of Dalpiciclib combined with Fulvestrant and Compound Gossyfol Acetate Tablets.
|
Throughout the experiment, assessed up to 24 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents, Male
- Spermatocidal Agents
- Antispermatogenic Agents
- Gossypol
- Gossypol acetic acid
Other Study ID Numbers
- HIM-B002a
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
-
Henan Cancer HospitalNot yet recruitingAdvanced Breast Cancer | Treatment | HR Low/HER2 Negative
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Henan Cancer HospitalRecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive,HER2-negative in Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerChina
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | PertuzumabChina
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Clinical Trials on dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingHigh-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)